Details for Patent: 9,840,505
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,840,505 protect, and when does it expire?
Patent 9,840,505 protects COPIKTRA and is included in one NDA.
This patent has forty patent family members in twenty-three countries.
Summary for Patent: 9,840,505
Title: | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Abstract: | Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof. |
Inventor(s): | Ren; Pingda (San Diego, CA), Martin; Michael (San Marcos, CA), Isbester; Paul (Castleton, NY), Lane; Benjamin S. (Lynnfield, MA), Kropp; Jason (Westford, MA) |
Assignee: | Infinity Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 15/016,117 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,840,505
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Secura | COPIKTRA | duvelisib | CAPSULE;ORAL | 211155-001 | Sep 24, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) | See Plans and Pricing | ||||
Secura | COPIKTRA | duvelisib | CAPSULE;ORAL | 211155-001 | Sep 24, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) | See Plans and Pricing | ||||
Secura | COPIKTRA | duvelisib | CAPSULE;ORAL | 211155-002 | Sep 24, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) | See Plans and Pricing | ||||
Secura | COPIKTRA | duvelisib | CAPSULE;ORAL | 211155-002 | Sep 24, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,840,505
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 084824 | See Plans and Pricing | |||
Argentina | 117467 | See Plans and Pricing | |||
Australia | 2012205669 | See Plans and Pricing | |||
Australia | 2015258280 | See Plans and Pricing | |||
Brazil | 112013017670 | See Plans and Pricing | |||
Canada | 2824197 | See Plans and Pricing | |||
Chile | 2013002007 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |